
|Videos|March 30, 2018
Dr. Matulonis Discusses Mirvetuximab Soravtansine Plus Pembrolizumab in Ovarian Cancer
Author(s)Ursula A. Matulonis, MD
Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-drug conjugate, with pembrolizumab (Keytruda) in patients with platinum-resistant epithelial ovarian cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
2
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
3
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
4
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
5









































